Abstract
Cholecystitis is an inflammation of the gallbladder caused by many causes like stone that is cholesterol gallstone and sometimes the cause is due to bacterial infection also known as acalculous cholecystitis. The risk factors for this disease are female, 40, fatty, fair, aging, diabetes mellitus, pregnancy, oral contraceptive and the most common factor is the interaction between genetic and environmental factors. Genetic factors include human leukocyte antigens, ethnicity, race and single nucleotide polymorphism in genes involved in the synthesis of cholesterol, transport and excretion.
Keywords
- cholecystitis
- genetic
- stone
- HLA
- ethnicity
1. Introduction
Cholecystitis is an inflammation of the gallbladder, originated from Greek word—
2. Causes
Cholecystitis is a gallbladder inflammation, which is most commonly caused by gallstones, tumor or scarring of the bile duct [7]. The greatest risk factor for calculous cholecystitis is gallstones and the risk factors for gallstones include female sex, increasing age more than 60, pregnancy, oral contraceptives, obesity, diabetes mellitus, ethnicity like Native North American or Mexican American ethnicity, rapid weight loss and drugs like hormonal replacement therapy in women during menopause. Cholesterol gallstones, accountable for about 90% of gallstones, due to supersaturation of bile with cholesterol stand for a multifactorial disease with a significant genetic component (Figure 1) [8].
A genetic factor in the vulnerability to gallstones was recognized as early as 1937 [10]. These stones were formed due to interactions of lithogenic alleles of gallstone susceptibility genes in DNA and many environmental factors [11]. The genetic cause may be due to fibroblast growth factor receptor 4 (FGFR4) polymorphism, which is a genetic risk factor contributing to aggravation of gallstone disease by maintaining bile acid homeostasis by regulating the expression of cholesterol 7α-hydroxylase (CYP7A1). The Gly388Arg (G-388R) had a greater inhibitory activity against bile acid biosynthesis and polymorphism in it affects stabilization and activation of FGFR4 and overexpression of FGFR4, especially the G-388R mutant of FGFR4 that inhibits luciferase activity of CYP7A1 reporter [12]. Acalculous cholecystitis is related to conditions associated with biliary stasis such as critical illness, major surgery or severe trauma/burns, sepsis, long-term total parenteral nutrition, prolonged fasting, myocardial infarction, sickle cell disease,
2.1. Genetic factor
Cholecystitis had been found in certain area of the world and had an epidemiological distribution raises an issue of genetic or chromosomal factors associated with it [16]. The frequency of diseases of the gallbladder, gallstones (cholelithiasis), cancer of the gallbladder and other biliary tract system diseases is more common in western countries (North America, Europe and Africa) [17]. This may be due to general response to some dietary or other environmental risk factor, suggesting a gene-environment interaction. The role of diet was attributed to the consumption of high-calorie, high-fat, low-fiber diets and insufficient exercise [18]. There was an epidemic of gallbladder disease among Amerindians and peoples genetically related to them [19]. The existence of this epidemic indicates a genetic basis of this disease. In addition to that, the prevalence of cholecystitis in geographically associated distribution may be related to genes of aboriginal Amerindian origin, the degree of Amerindian admixture. The person from New World genotype will do cholecystectomy by age 85 years and this constitutes about 40% in Mexican-American females and increased the risk of gallbladder cancer. Thus, genetic factor can be considered as Carcinogenic reason in New World peoples as any major environmental exposure [20]. The genetic effect in gallbladder diseases starts from chromosomal changes in gallbladder cells that leads to gallbladder cancer either acquired or inherent genetic instability in normal cells of the gallbladder causing mutational events that result in neoplastic transformation of normal cells and provide such cells with a selective growth over normal cells that leads to carcinoma of the gallbladder [21].The cause was due to loss of heterozygosity in the 3p, 8p, 9q and 22q chromosomal regions of cancer patients [22]. Other study demonstrated chromosomal aberrations were confined on chromosome 1’s long arm and translocation from the long arm of chromosome 4 to the long arm of chromosome 6. These aberrations constitutes about 16.6% and may be due to environmental effects, infections and inflammation [16]. The frequency of gallbladder disease was increased in Eastern populations like China, this may be due to the diet of the Chinese in Taiwan is already Westernized and differences among genetic populations [23]. The effect of genetic factor in the development of acute acalculous cholecystitis was manifested by infection with Epstein–Barr virus and development of disease [24]. Other microorganism that causes acalculous cholecystitis is
The class II molecule of HLA is a heterodimer consisting of two chains, an alpha (DRA) and a beta chain (DRB), both anchored in the membrane of the cell wall. HLA DRB1 plays a central role in the immune system by presenting peptides derived from extracellular proteins and the class II molecules are expressed in cell wall of antigen presenting cells B lymphocytes, dendritic cell and macrophages. The beta chain is approximately 26–28 kDa and is encoded by six exons. Exon 1 encodes the leader peptide; exons 2 and 3 encode the two extracellular domains; exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the polymorphisms of HLA that specifying the peptide binding specificities. Allelic variants of DRB1 are linked with many diseases [27]. Cholecystitis patients and control groups were typed for identifying the DRB1* alleles using DNA-based methodology (PCR-SSOP). Allele’s frequencies of HLA-DRB1 for cholecystitis patients and control group. There was an increased frequency of HLA-DRB1*03:01 in patients with cholecystitis compared with healthy controls (
Occurrence of genetic alterations is risk factors have been associated with gallbladder disease like cholecystitis, chronic inflammation of the gallbladder, congenital biliary abnormalities and polyps. Genetic predisposing factors associated with cancer of gallbladder like mutations in
2.2. Genetic cause of calculous cholecystitis disease
Gallstone disease is a very common biliary tract disease in the world. Gallstones are one of the most common and mainly costly digestive diseases in the developed countries. Geographic and ethnic differences in its occurrence imply that genetic factors influence risk of gallstone formation [14]. Its prevalence in the western countries was 48% [38], whereas in Asian ones was 5.9–21.9% [39]. It is a most common cause for cholecystitis, acute cholangitis and biliary pancreatitis. It is formed due to genetic-environmental factors interactions. Genetic factors that influence gallstone formation by its implication in different metabolic pathways, have been involved from linkage studies of twins, families study and ethnicities, it had been found that this disease is more common in siblings and other family members of affected persons than spouses or unrelated controls in a ratio 3:1 [40]. Twin studies have provided a clue into the genetic effect on disease development; the rates of this disease in monozygotic twins of both sexes were higher than in dizygotic twins [41]. This involves the genetic effects of multiple
Thus, in conclusion, there are a large number of genetic polymorphisms (SNPs) that causing calculus cholecystitis starting from cholesterol transporter [55], plasma transport [56], cholesteryl ester transfer protein [57] and cholesterol uptake [58], bile acid synthesis [59], transporter [60] and bilirubin excretion [61], mucin affect the formation of the gallstone genetically [62], gallbladder motility [63] and hormone receptor [64]. Thus, genetic study provided an insight toward the pathogenesis of the calculus cholecystitis.
2.3. Immunologic causes
The role of immune system on development of calculus and cholecystitis is manifested by cell-mediated immunity (Th1 cell) exerting its effect on formation of cholesterol gallstone and local inflammation [65]). It was first be confirmed by Lee and coworkers [66]. The proinflamatory cytokines had an effect on mucin production. Regarding immunoglobulins (particularly IgM and IgG), it had been found that they promote crystal nucleation [67]. This immune mechanism in the biliary system was altered due to the presence of multiple microbial flora [68] and other bacteria like enterohepatic
3. Conclusions
Inflammation of the gallbladder whether calculus or acalculous is a complex process mediated by genetic and environmental factors. Cholecystitis required a strong involvement of a genetic factor whether in the immune response infection against pathogen, formation of a stone and defense mechanism against inflammation. Understanding the concept of genetic factor leads to a novel diagnostic tools, treatments and preventive measures.
References
- 1.
Huffman JL, Schenker S. Acute acalculous cholecystitis—a review. Clin Gastroenterol Hepatol. 2010; 8:15–22. - 2.
Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med. 2008:358: 2804–11. - 3.
Friedman LS. Liver, biliary tract, & pancreas disorders. In Papadakis MA, McPhee SJ, Rabow MW (Eds), Current Medical Diagnosis & Treatment, 2015. Chapter 16, pp:658–715. - 4.
Demehri FR, Alam HB. Evidence-based management of common gallstone-related emergencies. J Int Care Med. 2016:31(1) 3–13. - 5.
Glasgow RE, Mulvihill SJ. Treatment of gallstone disease. In Feldman M, Friedman LS, Brandt LJ (Eds), Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia, PA: Saunders Elsevier; 2010: Chap. 66. - 6.
Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. Cancer J Clin. 2001:51:349–64. - 7.
Greenberger NJ, Paumgartner G. Chapter 311. Diseases of the Gallbladder and Bile Ducts. In Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J (Eds), ‘Harrison’s Principles of Internal Medicine, 18e.Retrieved November 08, 2014. - 8.
Casper M, Lammert F. Gallstone disease: Basic mechanisms, diagnosis and therapy. Praxis (Bern 1994). 2011:16:1403–12. - 9.
http://www.absarmohamed.com/2011/01/cholelithiasis-or-gall-stones.html - 10.
Buch S, Schafmayer C, Volzke H, Becker C, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007:39:995–9. - 11.
Wittenburg H. Hereditary liver disease: Gallstones. Best Pract Res Clin Gastroenterol. 2010:24:747–56. - 12.
Chuang SC, Hsi E, Lee KT. Genetics of gallstone disease. Adv Clin Chem. 2013:60:143–85. - 13.
Forbes LE, Bajaj M, McGinn T, et al. Perihepatic abscess formation in diabetes: A complication of silent gallstones. Am J Gastroenterol. 1996:91:786–8. - 14.
Chuang S-C, His E, Lee K-T. Genetics of gallstone disease Chapter five. Adv Clin Chem. 2013:60, 143–85. Elsevier Inc. - 15.
Evseeva IV. The determination in the polyclinic of the genetic risk for the development of chronic cholecystitis. Ter Arkh. 1994:66:67–70. - 16.
Dixit R, Kumar P, Tripathi R, Baus S, Mishra R, Shukla VK. Chromosomal structural analysis in carcinoma of the gallbladder. World J Surg Oncol. 2012:10:198. - 17.
Heaton K. Gallstones. In Trowell H, Burkitt D (Eds), Western Diseases. Cambridge, MA: Harvard Press, 1981, 47–60. - 18.
Trowell H, Burkitt D. Western Diseases: Their Emergence and Prevention. Cambridge, MA: Harvard Press, 1981. - 19.
Sampliner R, Bennett P, Comess L, Rose F, Burch T. Gallbladder disease in Pima Indians: Demonstration of high prevalence and early onset by cholecystography. N Engl J Med. 1970:283:1358–64. - 20.
Weiss KM, Ferrell RE, Hanis CL, Styne PN. Genetics and epidemiology of gallbladder disease in New World native peoples. Am J Hum Genet. 1984:36:1259–78. - 21.
Matsuo K, Kuroki T, Kitaoka F, Tajima Y, Kanematsu T. Loss of heterozygosity of chromosome 16q in gallbladder carcinoma. J Surg Res. 2002:102:133–6. - 22.
Wistuba II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, Gazdar AF. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer. 2002:87:432–40. - 23.
Chen J, Hsu C, Liu J, Tung T. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwa. BMC Gastroenterol. 2014:14:83. - 24.
Koufakis T, Gabranis I. Another report of acalculous cholecystitis in a Greek patient with infectious mononucleosis: A matter of luck or genetic predisposition? Case Report Hepatol. 2016:1–3. - 25.
Kim JH, Kang DH, Park SC. Draft genome sequence of human-pathogenic Lactococcus garvieae LG-ilsanpaik-gs201105 that caused acute acalculous cholecystitis. Genome Announc. 2015:3:e00464–15. - 26.
Festi D, Dormi A, Capodicasa S, Staniscia T, Attili AF, Loria P, et al. Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol. 2008:14:5282–9. - 27.
Neefjes JJ, Ploegh HL. Intracellular transport of MHC class II molecules. Immunol Today. 1992:13:179–84. - 28.
Al-Marzook TJ, Mutar Mahdi B, Raouf H, Zalzala HH, Abid LA, Nehad Z. The effect of HLA-DRB1 on cholecystitis. Iran J Immunol. 2015:12:149–55. - 29.
Sista F, Schietroma M, Santis GD, Mattei A, Cecilia EM, Piccione F, Leardi S, Carlei F, Amicucci G. Systemic inflammation and immune response after laparotomy vs laparoscopy in patients with acute cholecystitis, complicated by peritonitis. World J Gastrointest Surg. 2013:5:73–82. - 30.
Everhart JE. Gallstones and ethnicity in the Americas. J Assoc Acad Minor Phys. 2001:12:137–43. - 31.
Berntsen NL, Klingenberg O, Juran BD, Benito de Valle M, Lindkvist B, Lazaridis KN, et al. Association between HLA haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis. Gastroenterol. 2015:148:924–7. - 32.
Eslick GD. Epidemiology of gallbladder cancer. Gastroenterol Clin N Am. 2010:39:307–30. - 33.
Goldin RD, Roa JC. Gallbladder cancer: A morphological and molecular update. Histopathol. 2009:55:218–29. - 34.
Letelier P, Brebi P, Tapia O, Roa JC. DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer. Clin Epigenet. 2012:4:11. - 35.
House MG, Wistuba Ii, Argani P, et al. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol. 2003:10:882–9. - 36.
Takahashi T, Shivapurkar N, Riquelme E, et al. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res. 2004:10(18 Pt 1):6126–33. - 37.
Garcia P, Manterola C, Araya JC, et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. 2009:48:79–89. - 38.
Everhart JE, Yeh F, Lee ET, et al. Prevalence of gallbladder disease in American Indian populations: Findings from the Strong Heart Study. Hepatology. 2002:35:1507–12. - 39.
Lammert F, Sauerbruch T. Mechanisms of disease: The genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol. 2005:2:423–33. - 40.
Attili AF, De Santis A, Attili F, Roda E, Festi D, Carulli N. Prevalence of gallstone disease in first-degree relatives of patients with cholelithiasis. World J Gastroenterol. 2005:11:6508–11. - 41.
Antero Kesaniemi Y, Koskenvuo M, Vuoristo M, Miettinen TA. Biliary lipid composition in monozygotic and dizygotic pairs of twins. Gut. 1989:30:1750–6. - 42.
Hernández-Nazará A, Curiel-López F, Martínez-López E, Hernández-Nazará Z, Panduro A. Genetic predisposition of cholesterol gallstone disease. Ann Hepatol. 2006:5:140–9. - 43.
Kosters A, Jirsa M, Groen AK. Genetic background of cholesterol gallstone disease. Biochim Biophys Acta. 2003:1637:1–19. - 44.
Wang HH, Portincasa P, Wang DQ. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci. 2008:1:401–23. - 45.
Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology. 2001:120:1459–67. - 46.
Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 2003:23:315–22. - 47.
Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology. 2003:125:452–9. - 48.
Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002:110:109–17. - 49.
Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 1999:354:1341–6. - 50.
Grunhage F, Acalovschi M, Tirziu S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology. 2007:46:793–801. - 51.
King RA, Rotter JI, Motulsky AG, The Genetic Basis of Common Diseases, 2nd ed. Oxford, NY: Oxford University Press, 2002. - 52.
Wang DQ, Schmitz F, Kopin AS, Carey MC. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J Clin Invest. 2004:114:521–8. - 53.
Bertomeu A, Ros E, Zambon D, et al. Apolipoprotein E polymorphism and gallstones. Gastroenterol. 1996:111:1603–10. - 54.
Lohse P, Brewer HB, Meng MS, Skarlatos SI, LaRosa JC, Brewer HB. Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. J Lipid Res. 1992:33:1583–90. - 55.
Srivastava A, Srivastava K, Choudhuri G, Mittal B, Role of ABCG8 D19H (rs11887534) variant in gallstone susceptibility in northern India. J Gastroenterol Hepatol. 2010:25:1758–62. - 56.
Dixit M, Choudhuri G, Saxena R, Mittal B. Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease. Can J Gastroenterol. 2007:21:569–75. - 57.
Baez S, Tsuchiya Y, Calvo A, et al. Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J Gastroenterol. 2010:16:372–8. - 58.
Dixit D, Choudhuri G, Keshri LJ, Mittal B, Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J Gastroenterol Hepatol. 2006:21:847–9. - 59.
Chen Q, Li WJ, Wan YY, Yu CD, Li W. Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population. Genet Mol Res. 2012:8:548–55. - 60.
Srivastava A, Srivastava N, Choudhuri G, Mittal B, Organic anion transporter 1B1(SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CAgenotype in female patients in North India, Hepatol Res. 2011; 41: 71–8. - 61.
Heeney MM, Howard TA, Zimmerman SA, Ware RE, UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia, J Lab Clin Med. 2003;141: 279–82. - 62.
Chuang SC, Juo SH, His E, et al., Multiple mucin genes polymorphisms are associated with gallstone disease in Chinese men, Clin Chim Acta. 2011;412:599–603. - 63.
Klass DM, Lauer N, Hay B, Kratzer W, Fuchs M. Arg64 variant of the beta3-adrenergic receptor is associated with gallstone formation. Am J Gastroenterol. 2007:102:2482–7. - 64.
Kitsiou-Tzeli S, Giannatou E, Spanos I, et al. Steroid hormones polymorphisms and cholelithiasis in Greek population. Liver Int. 2007:27:61–8. - 65.
Whary MT, Morgan TJ, Dangler CA, Gaudes KJ, Taylor NS, Fox JG. Chronic active hepatitis induced by Helicobacter hepaticus in the A/JCr mouse is associated with a Th1 cell-mediated immune response. Infect Immun. 1998:66:3142–8. - 66.
Lee SP, Carey MC, LaMont JT. Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science. 1981:211:1429–31. - 67.
Miquel JF, Nunez L, Rigotti A, Amigo L, Brandan E, Nervi F. Isolation and partial characterization of cholesterol pronucleating hydrophobic glycoproteins associated to native biliary vesicles. FEBS Lett. 1993:318:45–9. - 68.
Abayli B, Colakoglu S, Serin M, Erdogan S, Isiksal YF, Tuncer I, Koksal F, Demiryurek H. Helicobacter pylori in the etiology of cholesterol gallstones. J Clin Gastroenterol. 2005:39:134–7. - 69.
Fox JG. Other helicobacters involved in human diseases. Acta Gastroenterol Belg. 2002:65:24–32. - 70.
Eaton KA, Mefford M, Thevenot T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol. 2001:166:7456–61. - 71.
Harvey PR, Upadhya GA, Strasberg SM. Immunoglobulins as nucleating proteins in the gallbladder bile of patients with cholesterol gallstones. J Biol Chem. 1991:266:13996–4003. - 72.
Huan P, Maosheng T, Zhiqian H, Long C, Xiaojun Y. TLR4 expression in normal gallbladder, chronic cholecystitis and gallbladder carcinoma. Hepatogastroenterol. 2012:59:42–6. - 73.
Sawada S, Harada K, Isse K, Sato Y, Sasaki M, Kaizaki Y, Nakanuma Y. Involvement of Escherichia coli in pathogenesis of xanthogranulomatous cholecystitis with scavenger receptor class A and CXCL16-CXCR6 interaction. Pathol Int. 2007:57:652–63.